Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27972754 | 1.00 | TSHR (0.62) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL5266157 | 0.98 | TSHR (0.64) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL125938 | 0.93 | TSHR (0.61) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL23149854 | 0.86 | TSHR (0.62) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL23149852 | 0.86 | TSHR (0.62) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL23706443 | 0.86 | TSHR (0.62) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL23706423 | 0.86 | TSHR (0.62) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL23706419 | 0.86 | TSHR (0.62) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL23706409 | 0.86 | TSHR (0.62) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL23706442 | 0.86 | TSHR (0.62) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4696696-A1 | IMMOBILIZED QUATERNARY PHOSPHONIUM SALT HAVING PHENOL DOMAIN, METHOD FOR PRODUCING SAME, AND CYCLIC CARBONATE PRODUCTION METHOD USING SAME | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2026-02-18 | — | — | EP | disclosed |
| US-20250381557-A1 | IMMOBILIZED ZINC COMPLEX HAVING GUANIDINE LIGAND, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING CYCLIC CARBONATE USING SAME | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-12-18 | — | — | US | disclosed |
| EP-4545543-A1 | IMMOBILIZED ZINC COMPLEX HAVING GUANIDINE LIGAND, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING CYCLIC CARBONATE USING SAME | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024214491-A1 | IMMOBILIZED QUATERNARY PHOSPHONIUM SALT HAVING PHENOL DOMAIN, METHOD FOR PRODUCING SAME, AND CYCLIC CARBONATE PRODUCTION METHOD USING SAME | 信越化学工業株式会社 | 2024-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381557-A1 | IMMOBILIZED ZINC COMPLEX HAVING GUANIDINE LIGAND, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING CYCLIC CARBONATE USING SAME | CA2, GRIA1, GUCY1A2 | TSHR 915/4885ALDH1A1 4014/4885TDP1 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.